Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is the Investigation About?

On March 27, 2025, BLCO disclosed that it had “[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)” and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses.

On this news, BLCO’s stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors.

Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that “as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.”

On this news, BLCO’s stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further.

Contact Us to Participate or Learn More:

If you purchased BLCO securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Century City, California 90067
Call us at: 310-914-5007
Email us at: [e-mail]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.